Cancer Genetics Risk Assessment and Counseling (PDQ®)–Health Professional Version
SECTIONS
- Introduction
- Cancer Risk Assessment and Counseling
- Components of the Risk Assessment Process
- Education and Counseling About Risk/Risk Communication
- The Option of Genetic Testing
- Ethical, Legal, and Social Implications
- Changes to This Summary (10/13/2016)
- About This PDQ Summary
- View All Sections
Changes to This Summary (10/13/2016)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that Table 3, Research Examining the Use of Multigene (Panel) Testing, comprises studies that included more than 1,000 participants. Also added text to state that the multigene panels are constantly changing and that variants of uncertain significance rates increase with the number of genes included on the panel (added Susswein et al. as reference 31).
Revised Table 3, Research Examining the Use of Multigene (Panel) Testing, to include a study of 10,030 consecutive patients who underwent cancer panel testing between August 2013 and October 2014 (cited Yurgelun et al. as reference 32) and a study of 1,462 patients who underwent breast/ovarian or colon cancer panel testing from November 2011 to June 2014 (cited Shirts et al. as reference 33).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summaryand PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario